Orlistat in the prevention of diabetes in the obese patient
Open accessThe DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Abstract
There has been an increase in the concern about preventing type 2 diabetes mellitus (T2DM), a disease with great and increasing prevalence. The prevalence of obesity, physical inactivity, Western processed diet, important risk factors for the development of T2DM, are also rising. Free fatty acids are increased in obesity and reduce insulin clearance and increase hepatic glucose production. Implementation of a healthy lifestyle has been show to slow the progression of impaired glucose tolerance to T2DM. Orlistat is an inhibitor of lipase activity, with proved efficacy in body weight reduction and long-term management of obesity and more favorable effects on carbohydrate metabolism and it was prospectively shown in XENDOS study that orlistat promoted long-term weight loss and prevented T2DM onset in obese individuals with normal and impaired glucose tolerance at baseline over four years. This benefit could be associated to the weight loss itself, to the limited absorption of lipids and reduction of plasma free fatty acids, to increased production of incretins or to modulation of secretion of cytokines by adipocytes, all effects secondary to orlistat treatment. A proposed strategy is to identify subjects at highest risk to receive a drug intervention, using lifestyle interventions alone at the community level.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011
Tuomilehto, J., Lindström, J., Eriksson, J. G., Valle, T. T., Hämäläinen, H., Ilanne-Parikka, P., Keinänen-Kiukaanniemi, S., Laakso, M., Louheranta, A., Rastas, M., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejm200105033441801 · Cited by 10,873 · cited 6×
“As formerly affirmed, a modest 10% weight reduction (Eriksson and Lindgarde 1991; Pan et al 1997; Swinburn et al 2001; Tuomilehto et al 2001; Knowler et al 2002; Kosaka et al 2005) and larger weight reduction through gastric surgery (Sjöström et al 2004; Pontiroli et al 2005) predict a reduced risk of T2DM.”
InfluentialDahlöf, B., Sever, P. S., Poulter, N. R., Wedel, H., Beevers, D. G., Caulfield, M., Collins, R., Kjeldsen, S. E., Kristinsson, A., McInnes, G. T., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67185-1 · Cited by 2,909
Diet, lifestyle, and the risk of type 2 diabetes mellitus in women.
Hu, F. B., Manson, J. E., Stampfer, M. J., Colditz, G., Liu, S., Solomon, C. G., & Willett, W. C. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010492 · Cited by 2,901
Inflammation: the link between insulin resistance, obesity and diabetes
Dandona, P. (2004) · Trends in Immunology · doi:10.1016/j.it.2003.10.013 · Cited by 2,170 · cited 1×
“Visceral fat is the source of a number of substances which might play a role in the development of a cronic infl amma-tory (Dandona et al 2004) and insulin-resistant state (Calles-Escandon and Cipolla 2001), as well as inadequate survival of pancreatic beta cells (Eldor and Raz 2006).”
Weight gain as a risk factor for clinical diabetes mellitus in women
Colditz, G. A., Willett, W. C., Rotnitzky, A., & Manson, J. E. (1995) · Annals of Internal Medicine · doi:10.7326/0003-4819-122-7-199504010-00001 · Cited by 2,064
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
U.K. Prospective Diabetes Study Group (1995) · Diabetes · doi:10.2337/diab.44.11.1249 · Cited by 1,923
XENical in the Prevention of Diabetes in Obese Subjects (XENDOS) Study
Torgerson, J. S., Hauptman, J., Boldrin, M. N., & Sjöström, L. (2004) · Diabetes Care · doi:10.2337/diacare.27.1.155 · Cited by 1,915
Obesity, Fat Distribution, and Weight Gain as Risk Factors for Clinical Diabetes in Men
Chan, J. M., Rimm, E. B., Colditz, G. A., Stampfer, M. J., & Willett, W. C. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.961 · Cited by 1,808 · cited 1×
“Moreover, waist circumference in the highest quintile was directly correlated to T2DM risk (Chan et al 1994).”
Chiasson, J.-L., Josse, R. G., Gomis, R., Hanefeld, M., Karasik, A., Laakso, M., & for The STOP-NIDDM Trial Research Group (2003) · JAMA · doi:10.1001/jama.290.4.486 · Cited by 1,624 · cited 1×
“…in the TRIPOD interventional study in Hispanic women with a history of gestational diabetes (Buchanan et al 2002); acarbose in the STOP-NIDDM trial (Chiasson et al 2003), and also likely in mid-analysis of the EDIT trial (Scheen 2003), and rosi-glitazone in the recently published DREAM trial…”
Lindholm, L. H., Ibsen, H., Dahlöf, B., Devereux, R. B., Beevers, G., de Faire, U., Fyhrquist, F., Julius, S., Kjeldsen, S. E., Kristiansson, K., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08090-x · Cited by 1,560
Lifetime risk for diabetes mellitus in the United States
Narayan, K. M. V. (2003) · JAMA · doi:10.1001/jama.290.14.1884 · Cited by 1,515 · cited 1×
“Moreover, the lifetime risk for developing T2DM was estimated to be 32.8% and 38.5%, respectively, for a man and a woman born in 2000 in the US (Narayan et al 2003).”
InfluentialBuchanan, T. A., Xiang, A. H., Peters, R. K., Kjos, S. L., Marroquin, A., Goico, J., Ochoa, C., Tan, S., Berkowitz, K., Hodis, H. N., et al. (2002) · Diabetes · doi:10.2337/diabetes.51.9.2796 · Cited by 1,339
Carbohydrates, dietary fiber, and incident type 2 diabetes in older women
Meyer, K. A., Kushi, L. H., Jacobs, D. R., Slavin, J., Sellers, T. A., & Folsom, A. R. (2000) · The American Journal of Clinical Nutrition · doi:10.1093/ajcn/71.4.921 · Cited by 1,271
Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237
Eriksson, K. F., & Lindg�rde, F. (1991) · Diabetologia · doi:10.1007/bf00400196 · Cited by 1,092 · cited 3×
“…Van Dam et al 2002) or enhancing the fi ber and magnesium content of the diet (Lopez-Ridaura et al 2004) – and/or physical activity promoting weight loss (Eriksson and Lindgarde 1991; Pan et al 1997; Swinburn et al 2001; Tuomilehto et al 2001; Knowler et al 2002; Kosaka et al 2005), smoking status…”
Effect of fatty acids on glucose production and utilization in man.
Ferrannini, E., Barrett, E. J., Bevilacqua, S., & DeFronzo, R. A. (1983) · Journal of Clinical Investigation · doi:10.1172/jci111133 · Cited by 1,050
Diabetes trends in the U.S.: 1990-1998.
Mokdad, A. H., Ford, E. S., Bowman, B. A., Nelson, D. E., Engelgau, M. M., Vinicor, F., & Marks, J. S. (2000) · Diabetes Care · doi:10.2337/diacare.23.9.1278 · Cited by 1,042 · cited 1×
“In the US, the prevalence of T2DM increased 33% from 1990 to 1998 (Mokdad et al 2000), was accountable for an estimated US$132 billion in direct and indirect costs in 2002 and T2DM is the fi fth leading cause of death (ADA 2003).”
Davidson, M. H., Hauptman, J., DiGirolamo, M., Foreyt, J. P., Halsted, C. H., Heber, D., Heimburger, D. C., Lucas, C. P., Robbins, D. C., Chung, J., et al. (1999) · JAMA · doi:10.1001/jama.281.3.235 · Cited by 947 · cited 1×
“The effi cacy of orlistat in body weight reduction and long-term management of obesity has been shown in two large multicentre randomized double-blind 2-year trials, with 1187 (Sjöström et al 1998) and 743 obese patients (Davidson et al 1999).”
Hu, F. B., Sigal, R. J., Rich-Edwards, J. W., Colditz, G. A., Solomon, C. G., Willett, W. C., Speizer, F. E., & Manson, J. E. (1999) · JAMA · doi:10.1001/jama.282.15.1433 · Cited by 914 · cited 1×
“Epidemiologic studies suggest that obesity and inactivity are substantial predictors for the development of T2DM among women (Hu et al 1999, 2001).”
Systematic Review: An Evaluation of Major Commercial Weight Loss Programs in the United States
Tsai, A. G., & Wadden, T. A. (2005) · Annals of Internal Medicine · doi:10.7326/0003-4819-142-1-200501040-00012 · Cited by 815 · cited 1×
“By the other hand, it is very clear that health providers need to assist their overweight patients with weight control (Tsai and Wadden 2005).”
Dietary Patterns and Risk for Type 2 Diabetes Mellitus in U.S. Men
van Dam, R. M., Rimm, E. B., Willett, W. C., Stampfer, M. J., & Hu, F. B. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-136-3-200202050-00008 · Cited by 801
Coffee Consumption and Risk of Type 2 Diabetes: A Systematic Review
van Dam, R. M., & Hu, F. B. (2005) · JAMA · doi:10.1001/jama.294.1.97 · Cited by 662 · cited 2×
“Among there antidiabetic agents are: metformin in the US DPP Study (Knowler et al 2002), and possibly in the mid-term 3-year analysis of the ongoing EDIT trial (Scheen 2003); troglitazone in the TRIPOD interventional study in Hispanic women with a history of gestational diabetes (Buchanan et al…”
Prevention of type 2 diabetes by lifestyle intervention: a Japanese trial in IGT males
Kosaka, K., Noda, M., & Kuzuya, T. (2005) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.06.010 · Cited by 656
Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654
Edelstein, S. L., Knowler, W. C., Bain, R. P., Andres, R., Barrett-Connor, E. L., Dowse, G. K., Haffner, S. M., Pettitt, D. J., Sorkin, J. D., Muller, D. C., et al. (1997) · Diabetes · doi:10.2337/diabetes.46.4.701 · Cited by 641
Diabetes mellitus in the Pima Indians: Incidence, risk factors and pathogenesis
Knowler, W. C., Pettitt, D. J., Saad, M. F., & Bennett, P. H. (1990) · Diabetes/Metabolism Reviews · doi:10.1002/dmr.5610060101 · Cited by 578 · cited 6×
“The prevalence of obesity was comparable in the Mexican Pima Indians (7% in men and 20% in women) and non-Pima Mexicans (respectively 9% and 27%), but much lower than in the US Pima Indians (respectively 64% and 75%).”
InfluentialPerry, I. J., Wannamethee, S. G., Walker, M. K., Thomson, A. G., Whincup, P. H., & Shaper, A. G. (1995) · BMJ · doi:10.1136/bmj.310.6979.560 · Cited by 532 · cited 1×
“In 7735 British men who were 40 to 59 years of age, moderate physical activity substantially diminished the risk of T2DM relative to sedentary men, after adjustment for BMI and age (Perry et al 1995).”
Vilsbøll, T., Krarup, T., Sonne, J., Madsbad, S., Vølund, A., Juul, A. G., & Holst, J. J. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2002-021873 · Cited by 528
Long-term Effects of Modest Weight Loss in Type II Diabetic Patients
Wing, R. R. (1987) · Archives of Internal Medicine · doi:10.1001/archinte.1987.00370100063012 · Cited by 484
Rössner, S., Sjöström, L., Noack, R., Meinders, A. E., Noseda, G., & Study, O. B. O. T. E. O. O. (2000) · Obesity Research · doi:10.1038/oby.2000.8 · Cited by 476
Santomauro, A. T., Boden, G., Silva, M. E., Rocha, D. M., Santos, R. F., Ursich, M. J., Strassmann, P. G., & Wajchenberg, B. L. (1999) · Diabetes · doi:10.2337/diabetes.48.9.1836 · Cited by 431 · cited 1×
“…many satisfactory and convincing studies have confi rmed that plasma levels of FFA can modulate the severity of insulin resistance in T2DM, inhibiting whole body glucose utilization and oxidation (Ferrannini et al 1983; Piatti et al 1996; Randle 1998; Santomauro et al 1999; Kelley et al 2001).”
Schulz, L. O., Bennett, P. H., Ravussin, E., Kidd, J. R., Kidd, K. K., Esparza, J., & Valencia, M. E. (2006) · Diabetes Care · doi:10.2337/dc06-0138 · Cited by 420 · cited 5×
“The prevalence of obesity was comparable in the Mexican Pima Indians (7% in men and 20% in women) and non-Pima Mexicans (respectively 9% and 27%), but much lower than in the US Pima Indians (respectively 64% and 75%).”
InfluentialKelley, D. E., Bray, G. A., Pi-Sunyer, F. X., Klein, S., Hill, J., Miles, J., & Hollander, P. (2002) · Diabetes Care · doi:10.2337/diacare.25.6.1033 · Cited by 314 · cited 1×
“…improvements in total cholesterol and LDL cholesterol compared with placebo in overweight and obese patients with T2DM treated with metformin, consistent with the reduction in LDL/HDL ratio documented in many studies (Sjöström et al 1998; Rossner et al 2000; Kelley et al 2002; Halpern et al 2003).”
Effect of orlistat in overweight and obese patients with type 2 diabetes treated with metformin
Miles, J. M., Leiter, L., Hollander, P., Wadden, T., Anderson, J. W., Doyle, M., Foreyt, J., Aronne, L., & Klein, S. (2002) · Diabetes Care · doi:10.2337/diacare.25.7.1123 · Cited by 286
Heart and Estrogen/progestin Replacement Study (HERS)
Grady, D., Applegate, W., Bush, T., Furberg, C., Riggs, B., & Hulley, S. B. (1998) · Controlled Clinical Trials · doi:10.1016/s0197-2456(98)00010-5 · Cited by 260
Swinburn, B. A., Metcalf, P. A., & Ley, S. J. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.619 · Cited by 240
The burden of overweight and obesity in the Asia–Pacific region
Asia Pacific Cohort Studies Collaboration (2007) · Obesity Reviews · doi:10.1111/j.1467-789x.2006.00292.x · Cited by 220
Williams, K. V., Mullen, M. L., Kelley, D. E., & Wing, R. R. (1998) · Diabetes Care · doi:10.2337/diacare.21.1.2 · Cited by 194
Pontiroli, A. E., Folli, F., Paganelli, M., Micheletto, G., Pizzocri, P., Vedani, P., Luisi, F., Perego, L., Morabito, A., & Bressani Doldi, S. (2005) · Diabetes Care · doi:10.2337/diacare.28.11.2703 · Cited by 129
Dietary fatty acids and insulin resistance
Lovejoy, J. C. (1999) · Current Atherosclerosis Reports · doi:10.1007/s11883-999-0035-5 · Cited by 86
Cited by
Glyoxalase 1 Modulation in Obesity and Diabetes
Rabbani, N., & Thornalley, P. J. (2019) · Antioxidants & Redox Signaling · doi:10.1089/ars.2017.7424 · Cited by 102
“There was a 5% decrease in FPG post-supplementation with tRES-HESP that exceeds that found in similar trials with metformin and matches that found with Olristat—a lipase inhibitor anti-obesity drug (107, 130).”
Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61
Treating diabetes and prediabetes by focusing on obesity management
Khaodhiar, L., Cummings, S., & Apovian, C. M. (2009) · Current Diabetes Reports · doi:10.1007/s11892-009-0055-0 · Cited by 56
Metadata
- Authors
- Mancini, M. C.
- Venue
- Vascular Health and Risk Management
- Publisher
- Informa UK Limited
- Published
- 2008-04
- Volume
- Volume 4
- Issue
- 2
- Pages
- 325-336
- ISSN
- 1176-6344 (ISSN-L)
- 1178-2048
- OpenAlex
- W1703519921
- Cited by
- 37
- References
- 44
- FWCI
- 1.24
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.